Status:
ACTIVE_NOT_RECRUITING
Multi-domain Online Therapeutic Investigation Of Neurocognition (MOTION)
Lead Sponsor:
University of California, San Francisco
Collaborating Sponsors:
San Francisco VA Health Care System
University of California, Los Angeles
Conditions:
Mild Cognitive Impairment
Subjective Memory Decline
Eligibility:
All Genders
55+ years
Phase:
NA
Brief Summary
The purpose of this study is to compare the effects of three on-line wellness interventions for improving physical and cognitive function and brain connectivity in adults who are at least 55 years old...
Detailed Description
The proposed study will perform a randomized, controlled trial (RCT) to compare the effects of three on-line wellness interventions for adults (age 55 years and older) who are experiencing memory and/...
Eligibility Criteria
Inclusion
- age ≥ 55 years
- subjective cognitive complaints, defined as self-experienced persistent decline in cognitive capacity in comparison with a previously normal status and unrelated to an acute event
- Montreal Cognitive Assessment (MoCA) score suggestive of Mild Cognitive Impairment (MCI) status (i.e., \< 26)
- English language fluency
- Wireless internet connection at home
- Willingness to travel to the San Francisco VA in northern California or UCLA in southern California for in-person assessments at baseline, after the 12-week interventions, and at the 36-week follow-up
- Capacity to provide informed consent or legally authorized representative consent and participant assent.
Exclusion
- current or past Axis I psychiatric disorders, or recent unstable medical or neurological disorders
- disabilities that prevent participation in on-line movement classes (e.g., primarily use wheel-chair, severe visual impairment that would limit ability to observe instructor's movement on screen or severe hearing impairment that would limit ability to hear instructor's directions)
- insufficient English proficiency
- limited life expectancy (i.e., enrolled in hospice, metastatic cancer)
- plan to travel for \> 1 week during 12-week intervention period
- diagnosis of dementia per the DSM-5
- MoCA score suggestive of dementia (i.e., \<17)
- started dementia medication (cholinesterase inhibitor or memantine) in past 3 months or plans to start dementia medication during study period
- planning to start/change any psychoactive medication during study period
- current participation in another research study
- contraindications to magnetic resonance imaging (MRI), including claustrophobia severe enough to prevent MRI examination, presence of ferrometallic objects in the body that would interfere with MRI examination and/or cause a safety risk (e.g., pacemakers, implanted stimulators, pumps)
- prior or current training in with Tai Chi, PLIE, or other mind-body practices
Key Trial Info
Start Date :
February 15 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 30 2026
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT05217849
Start Date
February 15 2022
End Date
June 30 2026
Last Update
December 23 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
VA Health Care System
San Francisco, California, United States, 94121